Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2016 3
2017 2
2018 5
2019 3
2020 6
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC; Tumor Neoantigen Selection Alliance; Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. Wells DK, et al. Among authors: hubbard lucey vm. Cell. 2020 Oct 29;183(3):818-834.e13. doi: 10.1016/j.cell.2020.09.015. Epub 2020 Oct 9. Cell. 2020. PMID: 33038342 Free PMC article.
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Padrón LJ, et al. Among authors: hubbard lucey vm. Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3. Nat Med. 2022. PMID: 35662283 Free PMC article. Clinical Trial.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Kluger HM, et al. Among authors: hubbard lucey vm. J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398. J Immunother Cancer. 2020. PMID: 32238470 Free PMC article.
Immuno-oncology drug development goes global.
Xin Yu J, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Among authors: hubbard lucey vm. Nat Rev Drug Discov. 2019 Nov;18(12):899-900. doi: 10.1038/d41573-019-00167-9. Nat Rev Drug Discov. 2019. PMID: 31780841 No abstract available.
Trends in the global immuno-oncology landscape.
Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Tang J, et al. Among authors: hubbard lucey vm. Nat Rev Drug Discov. 2018 Nov;17(11):783-784. doi: 10.1038/nrd.2018.167. Epub 2018 Oct 19. Nat Rev Drug Discov. 2018. PMID: 30337722 No abstract available.
Trends in the global immuno-oncology landscape.
Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Tang J, et al. Among authors: hubbard lucey vm. Nat Rev Drug Discov. 2018 Dec;17(12):922. doi: 10.1038/nrd.2018.202. Epub 2018 Oct 26. Nat Rev Drug Discov. 2018. PMID: 30361553
Cancer cell therapies: the clinical trial landscape.
Yu JX, Upadhaya S, Tatake R, Barkalow F, Hubbard-Lucey VM. Yu JX, et al. Among authors: hubbard lucey vm. Nat Rev Drug Discov. 2020 Sep;19(9):583-584. doi: 10.1038/d41573-020-00099-9. Nat Rev Drug Discov. 2020. PMID: 32457476 No abstract available.
Impact of COVID-19 on oncology clinical trials.
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Upadhaya S, et al. Among authors: hubbard lucey vm. Nat Rev Drug Discov. 2020 Jun;19(6):376-377. doi: 10.1038/d41573-020-00093-1. Nat Rev Drug Discov. 2020. PMID: 32424343 No abstract available.
24 results